Press Releases

March 26, 2024

Vigeo Therapeutics to Present at the 2024 Glioblastoma Drug Development Summit in Boston Massachusetts

July 13, 2023

Vigeo Therapeutics Provides Clinical Update on VT1021 Treatment of GBM Expansion Patient

June 02, 2023

Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session

May 25, 2023

Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion study in GBM Patients

May 19, 2023

Global Coalition for Adaptive Research and GBM AGILE Partners to Ring the Nasdaq Stock Market Closing Bell in Honor of National Brain Tumor Awareness Month

January 27, 2023

Groundbreaking discovery by Vigeo cofounder Randolph Watnick demonstrates a novel role of PRSS2 in creating an immunosuppressive tumor microenvironment.

July 06, 2022

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’s VT1021 in GBM Agile Trial

January 20, 2022

Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma

November 16, 2021

Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society of NeuroOncology’s 2021 Annual Meeting

November 09, 2021

Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting

October 01, 2021

Vigeo Therapeutics to Present New Phase 1/2 VT1021 Data from its Pancreatic Cancer Expansion Study at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting

September 21, 2021

Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer

November 09, 2020

Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer’s 2020 Annual Meeting

April 09, 2020

Vigeo Therapeutics Doses First Patients in Expansion Phase of its 1b/2 Study Investigating VT1021 in Patients with CD36 Expressing Cancers

October 15, 2019

Vigeo Therapeutics to Present at the 2019 BIO Investor Forum

September 26, 2019

Vigeo Therapeutics to Present Results from Its Phase 1 Study Evaluating VT1021 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology (ESMO) 2019 Congress

May 31, 2019

Vigeo Therapeutics Presents Preliminary Results from Its Phase 1 Open Label Trial of VT1021 in Patients with Advanced Solid Tumors at ASCO